TrialCompass TCL
Find TrialsAI AssistantLetter GeneratorAbout
Back to results
RecruitingPriority 4 · Lower priorityNCT00177268

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

ClinicalTrials.gov

Plain-language summary

This trial is studying Blood draw and skin biopsy or urine collection for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Blood draw, skin biopsy or urine collection (OTHER): Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.

Drugs / treatments
Blood draw, skin biopsy or urine collection
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

At a glance

Phase
Status
Recruiting
Design
Non-randomized, blind
Enrollment target
200 patients
Primary endpoint
Proteomics of Cutaneous T-cell lymphoma
Ages
18 Years to —
Start date
2004-10
Est. completion
2032-01

Locations

1 US sites · 1 total

Pennsylvania

Contact

Sponsor
University of Pittsburgh (OTHER)
Contact
Charity L Ruhl, LPN | ruhlcl@upmc.edu | 4126472013

Tags

CTCLany
TrialCompass — Clinical Trial Summary

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

NCT00177268

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying Blood draw and skin biopsy or urine collection for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Blood draw, skin biopsy or urine collection (OTHER): Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.

Drugs / treatments: Blood draw, skin biopsy or urine collection

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 200 patients

Primary endpoint: Proteomics of Cutaneous T-cell lymphoma

Ages: 18 Years to —

Start date: 2004-10 | Est. completion: 2032-01

Locations

1 US sites · 1 total

Pennsylvania

Contact

Charity L Ruhl, LPN | ruhlcl@upmc.edu | 4126472013

Sponsor: University of Pittsburgh (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT00177268

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.
TrialCompass

A free tool to help patients, caregivers, and clinicians find and understand clinical trials for T-cell lymphoma.

Explore

  • Find Trials
  • AI Assistant
  • Letter Generator
  • About
  • Share Your Feedback
  • Terms of Use
  • Privacy Policy

Data sourced from ClinicalTrials.gov.

For informational purposes only. Not medical advice — always consult your healthcare team.

Built with care for the rare cancer community.

Data last updated: June 2026

Edit with